63024-02-2

Basic information

• Product Name: L-Serine, N-[N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl]-O-(phenylmethyl)-, bis(phenylmethyl) ester
• CAS NO: 63024-02-2
• Molecular Formula: C33H38N2O8
• Molecular Weight: 590.673
• Mol File: 63024-02-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: L-Serine, N-[N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl]-O-(phenylmethyl)-, bis(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Serine, N-[N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl]-O-(phenylmethyl)-, bis(phenylmethyl) ester(63024-02-2)
• EPA Substance Registry System: L-Serine, N-[N-[(1,1-dimethylethoxy)carbonyl]-L-a-aspartyl]-O-(phenylmethyl)-, bis(phenylmethyl) ester(63024-02-2)

Safety Data

• Hazardous Substances Data: 63024-02-2(Hazardous Substances Data)

Upstream product

• 69871-79-0 (S)-benzyl 3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)propanoate 
• 100-39-0 benzyl bromide 
• 23680-31-1 BOC-O-benzyl-L-serine 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 1279028-21-5 (S)-benzyl 2-amino-3-(benzyloxy)propanoate hydrochloride 

Downstream Products

• 246516-47-2 Boc-Arg(N^gNO₂)-Gly-Asp(OBn)-Ser(Bn)-OBn 
• 788808-61-7 Arg(N^gNO₂)-Gly-Asp(OBn)-Ser(Bn)-OBn 
• 145877-80-1 (S)-3-(2-Amino-acetylamino)-N-((S)-2-benzyloxy-1-benzyloxycarbonyl-ethyl)-succinamic acid benzyl ester 
• 143783-29-3 Boc-Gly-Asp(OBzl)-Ser(Bzl)-OBzl 
• 246516-47-2 Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Ser(Bn)-OBn 
• 91037-65-9 H-Arg-Gly-Asp-Ser-OH 
• 906674-56-4 estrone-3-oxyacetyl-Arg(NO₂)-Gly-Asp(OBzl)-Ser(Bzl)-OBzl 
• 946144-06-5 estradiol-3-O-acetyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Ser(Bn)-OBn 
• 906673-83-4 estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Ser(Bn)-OBn 
• 139087-62-0 Asp-Ser(Bn)-OBn 

Relevant articles and documents

RGD-peptides modifying dexamethasone: to enhance the anti-inflammatory efficacy and limit the risk of osteoporosis

Dexamethasone (Dex) is one of the most effective anti-inflammatory glucocorticoids, while the side effect, osteoporosis seriously limits its clinical use. Cell adhesion is involved in the onset of inflammation and osteoporosis, and RGD-peptides are well k

Synthesis, evaluation and 3D QSAR analysis of novel estradiol-RGD octapeptide conjugates with oral anti-osteoporosis activity

To enhance the potency, reduce the side effects and improve oral property of estradiol in estrogen replacement therapy (ERT), 6 novel estradiol-RGD octapeptide conjugates have been prepared. In an ovariectomized mouse osteoporotic model, at an oral dosage

Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates

To improve the specificity and potency of estrogen replacement therapy therapeutics while also minimizing the side effects such as bone resorption and thickening of the uterine wall, a series of novel estrogen-derived conjugates estradiol-3-RGD, estradiol